The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.

Hatjiharissi, E; Terpos, E; Papaioannou, M; Hatjileontis, C; Kaloutsi, V; Galaktidou, G; Gerotziafas, G; Christakis, J; Zervas, K

Hatjiharissi, E; Terpos, E; Papaioannou, M; Hatjileontis, C; Kaloutsi, V; Galaktidou, G; Gerotziafas, G; Christakis, J; Zervas, K.

Affiliation

Hatjiharissi E; Department of Hematology, Theageneion Anticancer Center, Thessaloniki, Greece.

Hematol Oncol ; 22(4): 159-68, 2004 Dec.

Article in En | MEDLINE | ID: mdl-15991268

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bone Marrow/blood supply; Cytokines/blood; Multiple Myeloma/drug therapy; Neoplasm Proteins/blood; Neovascularization, Pathologic/blood; Aged; Dexamethasone/administration & dosage; Female; Fibroblast Growth Factor 2/blood; Humans; Interleukin-1/blood; Interleukin-6/blood; Male; Middle Aged; Multiple Myeloma/blood; Multiple Myeloma/pathology; Neovascularization, Pathologic/drug therapy; Neovascularization, Pathologic/etiology; Receptors, Interleukin-6/blood; Salvage Therapy; Solubility; Thalidomide/administration & dosage; Treatment Outcome; Tumor Necrosis Factor-alpha/analysis; Vascular Endothelial Growth Factor A/blood

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow / Antineoplastic Combined Chemotherapy Protocols / Cytokines / Multiple Myeloma / Neoplasm Proteins / Neovascularization, Pathologic Type of study: Etiology_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Hematol Oncol Year: 2004 Document type: Article Affiliation country: Greece Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links